Pheburane® (sodium phenylbutyrate) coverage to reach ~80% of commercially insured US patients by January 1st, 2024
26. Oktober 2023 07:30 ET
|
Medunik USA
PRINCETON, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Medunik USA (member of Duchesnay Pharmaceutical Group, an international company selected in the Government of Canada's first Global Hypergrowth...
SIKLOS® (hydroxyurea) is now covered by State Medicaid programs in 19 states
21. September 2023 07:30 ET
|
Medunik USA
PRINCETON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Medunik USA (member of Duchesnay Pharmaceutical Group) is pleased to announce that government coverage of Siklos® (hydroxyurea, HU) under State...
Pheburane® (sodium phenylbutyrate) coverage rapidly expands to the benefit of Americans with certain urea cycle disorders (UCDs)
09. August 2023 07:00 ET
|
Medunik USA
PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Medunik USA (member of Duchesnay Pharmaceutical Group) is pleased to announce that an increasing number of Americans with certain urea cycle...
Pheburane® Expanded Coverage with Commercial and Government (Medicaid) Payers
17. Mai 2023 10:45 ET
|
Medunik USA
PRINCETON, NJ, May 17, 2023 (GLOBE NEWSWIRE) -- Medunik USA (member of Duchesnay Pharmaceutical Group) is pleased to announce that Pheburane® is now covered with preferred status at key pharmacy...
Pheburane® Expanded Coverage with Commercial and Government (Medicaid) Payers
17. Mai 2023 07:00 ET
|
Medunik USA
PRINCETON, NJ, 17 mai 2023 (GLOBE NEWSWIRE) -- Medunik USA (member of Duchesnay Pharmaceutical Group) is pleased to announce that Pheburane® is now covered with preferred status at key pharmacy...
Medunik USA launches Pheburane® (sodium phenylbutyrate) oral pellets, a unique, taste-masked formulation of sodium phenylbutyrate (NaPB) used along with a specific diet for the long-term management of certain urea cycle disorders
06. September 2022 07:00 ET
|
Medunik USA
PRINCETON, NJ, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Medunik USA is pleased to announce the availability of Pheburane® oral pellets, a unique taste-masked formulation of sodium phenylbutyrate (NaPB). ...
Hydroxyurea-based treatment for sickle cell anemia previously available for pediatric patients now approved for use in adults
16. Februar 2022 07:00 ET
|
Medunik USA
ROSEMONT, PA, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Medunik USA is pleased to announce that Siklos® (hydroxyurea), previously indicated to reduce the frequency of painful crises and to reduce the need...